• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Vasoactive intestinal polypeptide infusion provokes migraine attacks

byJake EngelandMichael Pratte
August 9, 2021
in Chronic Disease, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Among patients with migraine without aura, 2-hour infusion of vasoactive intestinal polypeptide (VIP) initiated migraine attacks in 71% of participants compared to 5% after placebo infusion.

2. VIP infusion resulted in significantly greater dilation of the superficial temporal artery compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The release of vasoactive intestinal polypeptide (VIP) may be involved in provoking migraines through downstream signalling pathways on cranial vessels. This randomized controlled, crossover study investigated whether VIP infusion for two hours can initiate migraine attacks. Participants were included if they had previously been diagnosed with migraines without aura. They were recruited from the Danish Headache Centre between May 2020 and September 2020. Twenty-one participants were randomized to receive an intervention of VIP or placebo over two hours; two weeks following the first intervention, the participants received the intervention they had not received the first time. The primary outcome was the difference in the incidence of migraine attacks within 12 hours of intervention between VIP and placebo. Out of 21 participants, 15 had a migraine attack after VIP compared to 1 who had a migraine post-placebo infusion (15/21; 71% [95% CI: 48-89] vs. 1/21; 5% [95% CI: 0-24]; p< 0.001). The median time to migraine attack onset was 1 hour 40 minutes (IQR: 1 hour-1 hour 50 minutes), and the median headache intensity was 3/10 (IQR: 2-5). Nausea and photophobia were more commonly reported after VIP compared to placebo. In the hospital after infusion, superficial temporal artery (STA) diameter was recorded to assess vasodilation; STA diameter was significantly greater after VIP infusion compared to placebo (p< 0.001). When comparing this study to a previous study of VIP infusion in healthy volunteers, adverse events (flushing, warm sensation, heart palpitations) were similar between patients with migraines and healthy volunteers; however, migraine attacks and associated symptoms (nausea, photophobia, phonophobia) were more common among patients with previous migraines. Overall, VIP infusion for 2 hours induced migraine attacks and resulted in prolonged STA dilation in migraine patients without aura. This study was limited, however, by its generalizability as the sample size was small (21 participants), participants were recruited from one centre, and only those with migraine without aura were included.

Click to read the study in JAMA Network Open

Relevant Reading: PAPCAP38 induces migraine-like attacks in patients with migraine without aura

RELATED REPORTS

Antithrombotic agents may be effective in preventing migraine in patients with patent foramen ovale

Calcitonin gene-related peptide therapies effective for chronic migraine

Acupuncture may reduce pain and improve function in patients with migraine without aura

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: migrainemigrainesVasoactive intestinal polypeptide
Previous Post

Napping associated with improved performance in memory tasks  

Next Post

3-item stroke scale for large vessel occlusion associated with improved rates of endovascular stroke treatment

RelatedReports

Prochlorperazine for migraine may lower likelihood of ED return
Chronic Disease

Antithrombotic agents may be effective in preventing migraine in patients with patent foramen ovale

August 7, 2026
Galcanezumab reduces the frequency of episodic cluster headaches
Chronic Disease

Calcitonin gene-related peptide therapies effective for chronic migraine

May 4, 2026
Migraines associated with an increased risk of cardiovascular events in women
Chronic Disease

Acupuncture may reduce pain and improve function in patients with migraine without aura

February 2, 2026
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Weekly Rewinds

2 Minute Medicine Rewind February 2, 2026

February 2, 2026
Next Post
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

3-item stroke scale for large vessel occlusion associated with improved rates of endovascular stroke treatment

Galcanezumab reduces the frequency of episodic cluster headaches

Effect of vasoactive intestinal polypeptide on development of migraine headaches

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Checkpoint inhibitors show some benefit in patients with microsatellite stable metastatic colorectal cancer without liver metastases

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • A healthy lifestyle may reduce risk of infection in patients with type 2 diabetes
  • Fexofenadine and famotidine lack clinical trial evidence for menopausal symptoms
  • Lower levels of education and place of birth were associated with non-admission to the intensive care unit in Sweden during COVID-19 pandemic
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.